For people with diabetes treated with insulin, Dexcom rtCGM is associated with significant improvements over patients’ lifetimes and is likely to be cost-saving to the NHS
. | May 3, 2023
For people with diabetes treated with insulin, Dexcom rtCGM is associated with significant improvements over patients' lifetimes and is likely to be cost-saving to the NHS DexCom, Inc. (NASDAQ:DXCM)